Protagonist Therapeutics, Inc.

PTGX

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$154.71

+$0.40 · +0.26%

Aug 24, 3:55 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

36/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

Overpriced

Momentum

Gaining

Sentiment

Mixed

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Dinesh V. Patel
Listed since: Aug 11, 2016
Employees: 141

Market position

Volume: 0; 0× average
Average volume: 657.31K; Average daily volume
Market cap: 9.95B USD
Beta: 1.79; Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 5.43B USD
P/E (TTM): 127.02×
P/B (TTM): 12.12×
P/S (TTM): 35.29×
EV / EBITDA: -42.43×
Earnings yield: -2.34%
Free cash flow yield: 1.01%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 99.86%
Operating margin: 20.69%
Net margin: 29.40%
Return on equity: -21.17%
Return on assets: -19.43%
Return on invested capital: -25.23%

Financial health

Debt / equity: 0.01×
Current ratio: 12.71×
Altman Z-score: 136.53
Piotroski F-score: 6 of 9

Earnings

Latest fiscal-year EPS: -2.05; FY2025 · -148.46% year over year
Latest fiscal-year revenue: 46.02M USD; FY2025 · -89.41% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

PTGX news

accessnewswire.comAug 18, 2026

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in accordance with the…

Read source

fool.comAug 13, 2026

Which Small-Cap ETF Is the Better Buy: iShares' Growth-Focused IWO or Invesco's Revenue-Weighted RWJ?

Small-cap stocks are surging, but how you own them matters more than most investors realize.

Read source

seekingalpha.comAug 12, 2026

Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement

Protagonist Therapeutics (PTGX) maintains a "Strong Buy" rating, driven by FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis and strong partnership economics. Company is advancing rusfertide for…

Read source

zacks.comAug 11, 2026

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

Read source

fool.comAug 7, 2026

Which Growth ETF Is the Better Long-Term Buy: Vanguard's Mega Cap MGK or Invesco's Small-Cap RZG?

Vanguard's tech-heavy portfolio delivered stronger five-year returns despite higher volatility, while Invesco's small-cap approach offers broader sector diversification.

Read source

zacks.comAug 7, 2026

Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock

Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Read source